Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rodney Badger

Interventional Cardiology Orem, UT Medical Doctor

NPI 1003874439 CMS profile 317721

700 W 800 N Ste 444, Orem, UT 84057

Open in the dashboard

General payments

$10,628

179 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rodney Badger of Orem, UT is reported in the CMS Open Payments database as having received $10,628 across 179 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $466 10
2024 General $918 24
2023 General $2,304 18
2022 General $1,759 32
2021 General $2,139 30
2020 General $1,253 22
2019 General $1,789 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rodney Badger
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Rodney Badger were reported at $466. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Rodney Badger Interventional Cardiology median Middle half National median
2019 $1,789 $1,097 $329–$3,048 $163
2020 $1,253 $473 $161–$1,480 $114
2021 $2,139 $677 $233–$1,827 $132
2022 $1,759 $978 $333–$2,724 $149
2023 $2,304 $1,136 $382–$2,986 $160
2024 $918 $1,181 $395–$3,326 $164
2025 $466 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merit Medical Systems Inc $2,177 3 payments
  2. Medtronic, Inc. $1,236 22 payments
  3. Abiomed $1,157 28 payments
  4. Medtronic Vascular, Inc. $1,095 27 payments
  5. Boston Scientific Corporation $851 18 payments
  6. Inari Medical, Inc. $764 7 payments
  7. Biotronik Inc. $669 12 payments
  8. Shockwave Medical, Inc $429 8 payments
  9. Abbott Laboratories $367 5 payments
  10. Bard Peripheral Vascular, Inc. $306 4 payments
  11. Other $1,576 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,382 175 payments
  2. Consulting Fee $2,134 2 payments
  3. Education $69 1 payment
  4. Travel and Lodging $43 1 payment
Products named General payments · program years 2019–2025
  1. Impress Catheters $2,177 3 payments
  2. Impella $1,124 27 payments
  3. Resolute Stents $921 21 payments
  4. CT THROMBECTOMY SYSTEM KIT $764 7 payments
  5. FLOWTRIEVER CATHETER, S $764 7 payments
  6. RESOLUTE ONYX $442 7 payments
  7. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $429 8 payments
  8. WATCHMAN Access System $310 3 payments
  9. SAPIEN 3 Ultra RESILIA $277 2 payments
  10. Resolute Stents $231 6 payments
  11. Other $4,157 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

226

Median for Cardiac Surgery: 68

Drug cost

$11,844

Median for Cardiac Surgery: $445

Branded share of claims

46.9%

Median for Cardiac Surgery: 15.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 13 $10,366
Clopidogrel Clopidogrel Bisulfate Brand 93 $804
Atorvastatin Calcium Generic 26 $245
Lisinopril Generic 22 $140
Metoprolol Tartrate Generic 29 $120
Amlodipine Besylate Generic 26 $85
Rosuvastatin Calcium Generic 17 $84

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 411 Part D prescribers listed as Cardiac Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$51,951

Medicare's payments for the services billed

Medicare patients

109

Average age 78

Services billed

363

49 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 63%
Atrial fibrillation 50%
Chronic kidney disease 50%
Arthritis 49%
Diabetes 47%
Depression 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

179 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record